---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-018242"
form_type: "8-K"
ticker: "MDGL"
cik: "0001157601"
company_name: "MADRIGAL PHARMACEUTICALS, INC."
filed_at: "2025-04-17T23:59:59+00:00"
generated_at: "2026-05-23T11:32:58.083558+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Madrigal CMO/President of R&D Rebecca Taub steps down, becomes Senior Advisor through Dec 2025

## Summary
- Dr. Taub transitions from CMO and President of R&D to Senior Scientific and Medical Advisor effective April 21, 2025, through end of 2025.
- She will continue to serve on Madrigal's Board of Directors.
- Will receive base salary of $621,000 through Dec 31, 2025, and eligible for a 50% target bonus.
- Entered a Severance and Change of Control Agreement with standard severance: 12-month salary continuation, equity acceleration, and health benefits.
- No successor named; Taub will provide transition support and scientific guidance for MASH programs.

## SEC filing metadata
- accession: 0001628280-25-018242
- form_type: 8-K
- ticker: MDGL
- cik: 0001157601
- company_name: MADRIGAL PHARMACEUTICALS, INC.
- filed_at: 2025-04-17T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1157601/000162828025018242/0001628280-25-018242-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1157601/000162828025018242/mdgl-20250416.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-018242
- JSON: https://secwatch.observer/filing/0001628280-25-018242.json
- Plain text: https://secwatch.observer/filing/0001628280-25-018242.txt

## Key facts
- Executive change
  Rebecca Taub changed role as Senior Scientific and Medical Advisor at MADRIGAL PHARMACEUTICALS, INC..
  - Action: transitioned
  - Role: Senior Scientific and Medical Advisor
  source text: Pursuant to the Letter Agreement, effective as of April 21, 2025, Dr. Taub will transition from her current role and responsibilities to a new role as a Senior Scientific and Medical Advisor to the Company through the end of 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1157601/000162828025018242/0001628280-25-018242-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.